RESUMEN
The production of fully immunologically competent humanized mice engrafted with peripheral lymphocyte populations provides a model for in vivo testing of new vaccines, the durability of immunological memory and cancer therapies. This approach is limited, however, by the failure to efficiently engraft human B lymphocytes in immunodeficient mice. We hypothesized that this deficiency was due to the failure of the murine microenvironment to support human B cell survival. We report that while the human B lymphocyte survival factor, B lymphocyte stimulator (BLyS/BAFF) enhances the survival of human B cells ex vivo, murine BLyS has no such protective effect. Although human B cells bound both human and murine BLyS, nuclear accumulation of NF-kappaB p52, an indication of the induction of a protective anti-apoptotic response, following stimulation with human BLyS was more robust than that induced with murine BLyS suggesting a fundamental disparity in BLyS receptor signaling. Efficient engraftment of both human B and T lymphocytes in NOD rag1(-/-) Prf1(-/-) immunodeficient mice treated with recombinant human BLyS is observed after adoptive transfer of human PBL relative to PBS treated controls. Human BLyS treated recipients had on average 40-fold higher levels of serum Ig than controls and mounted a de novo antibody response to the thymus-independent antigens in pneumovax vaccine. The data indicate that production of fully immunologically competent humanized mice from PBL can be markedly facilitated by providing human BLyS.
Asunto(s)
Linfocitos B/metabolismo , Receptores del Factor de Necrosis Tumoral/fisiología , Animales , Antígenos CD19/biosíntesis , Linfocitos B/citología , Núcleo Celular/metabolismo , Separación Celular , Citometría de Flujo , Humanos , Ratones , Ratones Endogámicos NOD , Ratones SCID , FN-kappa B/metabolismo , Vacunas Neumococicas/uso terapéutico , Receptores del Factor de Necrosis Tumoral/metabolismo , Proteínas Recombinantes/química , Transducción de SeñalRESUMEN
Umbilical cord blood (UCB) is increasingly being used for human hematopoietic stem cell (HSC) transplantation in children but often requires pooling multiple cords to obtain sufficient numbers for transplantation in adults. To overcome this limitation, we have used an ex vivo two-week culture system to expand the number of hematopoietic CD34(+) cells in cord blood. To assess the in vivo function of these expanded CD34(+) cells, cultured human UCB containing 1 x 10(6) CD34(+) cells were transplanted into conditioned NOD-scid IL2rgamma(null) mice. The expanded CD34(+) cells displayed short- and long-term repopulating cell activity. The cultured human cells differentiated into myeloid, B-lymphoid, and erythroid lineages, but not T lymphocytes. Administration of human recombinant TNFalpha to recipient mice immediately prior to transplantation promoted human thymocyte and T-cell development. These T cells proliferated vigorously in response to TCR cross-linking by anti-CD3 antibody. Engrafted TNFalpha-treated mice generated antibodies in response to T-dependent and T-independent immunization, which was enhanced when mice were co-treated with the B cell cytokine BLyS. Ex vivo expanded CD34(+) human UCB cells have the capacity to generate multiple hematopoietic lineages and a functional human immune system upon transplantation into TNFalpha-treated NOD-scid IL2rgamma(null) mice.
Asunto(s)
Trasplante de Células Madre de Sangre del Cordón Umbilical , Subunidad gamma Común de Receptores de Interleucina/deficiencia , Animales , Antígenos CD34/sangre , Linfocitos B/citología , Linfocitos B/inmunología , Técnicas de Cultivo de Célula/métodos , Femenino , Hematopoyesis , Humanos , Recién Nacido , Subunidad gamma Común de Receptores de Interleucina/genética , Activación de Linfocitos , Linfopoyesis , Masculino , Ratones , Ratones Endogámicos NOD , Ratones Noqueados , Ratones SCID , Proteínas Recombinantes/administración & dosificación , Linfocitos T/citología , Linfocitos T/inmunología , Acondicionamiento Pretrasplante , Trasplante Heterólogo , Factor de Necrosis Tumoral alfa/administración & dosificaciónAsunto(s)
Consumo de Oxígeno/efectos de los fármacos , Choque Hemorrágico/fisiopatología , Vitamina A/análogos & derivados , Vitamina A/uso terapéutico , Animales , Presión Sanguínea/efectos de los fármacos , Carotenoides , Modelos Animales de Enfermedad , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Terapia por Inhalación de Oxígeno , Ratas , Ratas Sprague-Dawley , Choque Hemorrágico/tratamiento farmacológico , Vitamina A/farmacologíaRESUMEN
A new drug, trans sodium crocetinate (TSC), has been suggested for use in resuscitation after trauma. TSC has been shown to increase survival in a rat model of hemorrhagic shock. It also results in an increase in blood pressure and a decrease in plasma lactate levels when given immediately after hemorrhage. TSC increases whole-body oxygen consumption rates, and it is thought that its physiological effects are due to the increased oxygen availability. In fact, TSC therapy and 100% oxygen therapy show similar results when used in the same rat hemorrhage model. It has been suggested, however, that 100% oxygen therapy is effective only if begun immediately after hemorrhage. Such a window of opportunity has been said to exist for other resuscitation methods; thus, the current study is to determine if this is true for TSC. In one series of experiments, rats were bled 60% of their blood volumes and given an injection of TSC (or saline) 20 min after the hemorrhage ended. The injection was then repeated four times, spaced 10 min apart. Thirty minutes after the final injection, the animals were infused with normal saline. TSC again restored blood pressure and other parameters, but repeated dosing was necessary. In addition, this therapy prevented an increase in liver enzymes (transaminases) as measured 24 h after hemorrhage. In a second study, rats were bled 60% of their blood volumes, followed by a second bleeding (an additional 10%) done 10 min later. No subsequent fluid was infused in this group. The majority of the animals treated with TSC after the second hemorrhage survived, whereas the controls did not. These data suggest that TSC is effective when given after a delay. The dosing regimen must be different, however, presumably because of the blood acidosis that develops after hemorrhage. The results also suggest that TSC may be protective against secondary liver damage resulting from trauma.